A detailed history of Fulcrum Capital LLC transactions in Abb Vie Inc. stock. As of the latest transaction made, Fulcrum Capital LLC holds 1,979 shares of ABBV stock, worth $352,281. This represents 0.09% of its overall portfolio holdings.

Number of Shares
1,979
Previous 1,979 -0.0%
Holding current value
$352,281
Previous $339,000 15.04%
% of portfolio
0.09%
Previous 0.08%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2023

Jul 27, 2023

SELL
$132.51 - $164.9 $69,567 - $86,572
-525 Reduced 20.97%
1,979 $266,000
Q1 2023

May 10, 2023

BUY
$144.61 - $166.54 $142,730 - $164,374
987 Added 65.06%
2,504 $399,000
Q3 2022

Oct 17, 2022

BUY
$134.21 - $153.93 $13,421 - $15,393
100 Added 7.06%
1,517 $204,000
Q2 2022

Aug 03, 2022

BUY
$137.62 - $174.96 $195,007 - $247,918
1,417 New
1,417 $217,000
Q3 2021

Oct 21, 2021

SELL
$106.4 - $120.78 $378,252 - $429,372
-3,555 Closed
0 $0
Q2 2021

Jul 30, 2021

SELL
$105.21 - $117.21 $84,062 - $93,650
-799 Reduced 18.35%
3,555 $400,000
Q1 2021

Apr 12, 2021

SELL
$102.3 - $112.62 $25,984 - $28,605
-254 Reduced 5.51%
4,354 $471,000
Q4 2020

Feb 09, 2021

BUY
$80.49 - $108.67 $370,897 - $500,751
4,608 New
4,608 $494,000
Q3 2020

Oct 21, 2020

SELL
$85.91 - $100.83 $196,046 - $230,094
-2,282 Closed
0 $0
Q2 2020

Jul 27, 2020

BUY
$73.37 - $98.18 $167,430 - $224,046
2,282 New
2,282 $224,000
Q1 2020

May 01, 2020

SELL
$64.5 - $97.79 $147,189 - $223,156
-2,282 Closed
0 $0
Q4 2019

Feb 03, 2020

BUY
$72.13 - $90.25 $164,600 - $205,950
2,282 New
2,282 $202,000
Q2 2019

Jul 29, 2019

SELL
$65.7 - $83.98 $190,267 - $243,206
-2,896 Closed
0 $0
Q1 2019

May 08, 2019

BUY
$77.14 - $90.79 $223,397 - $262,927
2,896 New
2,896 $233,000

Others Institutions Holding ABBV

About AbbVie Inc.


  • Ticker ABBV
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 1,768,099,968
  • Market Cap $315B
  • Description
  • AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheuma...
More about ABBV
Track This Portfolio

Track Fulcrum Capital LLC Portfolio

Follow Fulcrum Capital LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Fulcrum Capital LLC, based on Form 13F filings with the SEC.

News

Stay updated on Fulcrum Capital LLC with notifications on news.